New Vaccine Could Stop Lung Cancer Before It Starts

Lung cancer, the third most common cancer in the UK, tragically results in tens of thousands of deaths annually, with diagnoses often occurring too late for effective treatment. Over 43,000 people are diagnosed each year, and approximately 33,000 succumb to the disease, with survival rates for 10 years or more being low.

Scientific advancements are ushering in a new era for combating lung cancer. Researchers are preparing to launch clinical trials for a preventive vaccine aimed at significantly reducing the risk of developing the disease. This initiative is supported by Cancer Research UK, a leading global funder of cancer research.

The complexity of lung cancer, with its diverse cell groups and ability to evolve resistance, makes it challenging to treat. Research, such as the extensive TRACERx study, is mapping how lung cancers develop and adapt, providing crucial insights into their evolutionary paths. This understanding is key to developing strategies for earlier detection and prevention.

Building on this research, the world's first vaccine designed to prevent lung cancer, LungVax, is emerging. LungVax trains the immune system to recognize early warning signs in lung cells, enabling the elimination of precancerous cells. The first human trials are anticipated to commence shortly, focusing on individuals at high risk of recurrence or new cancer development.

Beyond prevention, research derived from TRACERx is also leading to advancements like a blood test capable of detecting cancer recurrence earlier than current scans. This work also investigates the role of environmental factors, such as air pollution, in cancer development and identifies potential drug targets.